Muir Kevin 4

What Happened
Kevin Muir, General Manager, Interventional Oncology at Delcath Systems, received equity awards on February 17, 2026: a derivative option award for 56,500 shares (recorded at $0.00) and 28,250 restricted stock units (RSUs) (recorded at $0.00). Total awards = 84,750 units. These were grants/awards (not open-market purchases or sales), so they represent compensation equity rather than an investment transaction with cash changing hands at the time of grant.

Key Details

• Transaction date: February 17, 2026; Form 4 filed February 18, 2026 (timely filing).
• Awards: 56,500 derivative (option) units @ $0.00; 28,250 RSUs @ $0.00; total 84,750.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes:
  • F1: Option vests 1/36th per month starting Feb 17, 2026, subject to continued employment and plan terms.
  • F2: Each RSU converts to one share of common stock upon settlement.
  • F3: RSU vesting schedule — one-third vests Feb 17, 2027; the remaining two-thirds vest in equal annual installments over the next two years, subject to continued service.
• No immediate sale or exercise reported; no cash proceeds shown.

Context
These are compensation grants: options require vesting (and later exercise) to become shares, while RSUs convert to shares when they vest/settle. Because the filing records awards (A) and not purchases or sales, this is not a market-direction trade signal but rather management/employee compensation that will dilute when shares are issued/settled. Check company disclosures (proxy, equity plan) for exercise price and potential dilution details.